BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd. (BVXV) Company Profile & Overview
Explore BiondVax Pharmaceuticals Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
BiondVax Pharmaceuticals Ltd. (BVXV) Company Profile & Overview
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.